Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Panel Rejects New Use for Forest Heart Drug

By Pharmaceutical Processing | January 12, 2010

MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — Federal health advisers on Monday unanimously rejected a new use of Forest Laboratories’ hypertension drug for patients at risk of heart failure. The Food and Drug Administration’s outside panel of heart specialists voted 8-0 against approving Bystolic to prevent death or hospitalization caused by heart failure, according to an agency spokeswoman. The FDA is not required to follow the group’s advice, though it usually does. Forest already markets Bystolic to treat hypertension, or high blood pressure. An additional approval for heart failure would potentially expand the drug’s market to roughly 5.7 million U.S. patients with the disease. FDA reviewers said in documents issued last week that company data on the new use for Bystolic “lack robustness,” and don’t show a clear advantage for the drug. New York-based Forest tracked 2,000 elderly patients at risk for heart failure who received either Bystolic or a dummy pill. The difference in cardiac death and hospitalization due to heart failure between the groups was not statistically significant, according to the FDA. Agency reviewers also complained that the company made major adjustments to the design of the trial over the course of its four-year timespan. The FDA also raised questions about whether Forest’s study — which was conducted abroad — was applicable to U.S. medical practice. Bystolic is a member of the beta blocker family of medications, which are used to help lower dangerously high blood pressure. Forest reported $69.2 million in Bystolic sales for fiscal 2009, according to the company’s annual report. Competing drugs in the class include generic versions of AstraZeneca’s Toprol and GlaxoSmithKline’s Coreg. Beta blockers were the fifth most commonly prescribed drug in the U.S. during 2008, with 130 million prescriptions, according to health care research firm IMS Health. Shares of Forest Laboratories rose 36 cents to close at $31.40 on Monday.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE